These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28799202)

  • 1. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.
    Schroeder JA; Chen Y; Fang J; Wilcox DA; Shi Q
    J Thromb Haemost; 2014 Aug; 12(8):1283-93. PubMed ID: 24931217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
    Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
    Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q; Schroeder JA; Kuether EL; Montgomery RR
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.
    Jing W; Baumgartner CK; Xue F; Schroeder JA; Shi Q
    J Thromb Haemost; 2023 Mar; 21(3):488-498. PubMed ID: 36696197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
    Cai Y; Shi Q
    Front Immunol; 2020; 11():964. PubMed ID: 32595633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
    Liu CL; Ye P; Lin J; Djukovic D; Miao CH
    J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
    Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
    Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
    Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
    Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
    Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
    Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.
    Miao CH; Harmeling BR; Ziegler SF; Yen BC; Torgerson T; Chen L; Yau RJ; Peng B; Thompson AR; Ochs HD; Rawlings DJ
    Blood; 2009 Nov; 114(19):4034-44. PubMed ID: 19713458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
    Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
    J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
    Liu CL; Ye P; Yen BC; Miao CH
    Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
    Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
    Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
    J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
    Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.